PFAS and Kidney Cancer: The Scientific Evidence
Kidney cancer — specifically renal cell carcinoma, which accounts for approximately 90% of kidney cancers — has the most extensively documented association with PFAS exposure of any malignancy. When the International Agency for Research on Cancer evaluated the carcinogenicity of PFOA in November 2023, the agency's working group classified PFOA as a Group 1 carcinogen — the highest classification — based primarily on the strength of evidence linking it to kidney cancer in humans.
The C8 Science Panel determined a "probable link" between PFOA exposure and kidney cancer after analyzing health data from 69,000 residents in the Mid-Ohio Valley. The panel found that individuals with higher PFOA blood levels had significantly elevated rates of kidney cancer diagnosis. Subsequent meta-analyses have quantified this risk, with Mastrantonio et al. (2023) finding a relative risk of 1.74 for kidney cancer among individuals with high PFAS exposure — meaning they are 74% more likely to develop kidney cancer than unexposed individuals.
The biological mechanism linking PFAS to kidney cancer involves several pathways. PFAS activate peroxisome proliferator-activated receptor alpha (PPARa), promoting cellular proliferation in the kidney. They generate oxidative stress that damages renal cell DNA and interfere with DNA repair mechanisms. PFAS also disrupt signaling pathways involved in cell growth regulation, including the VHL tumor suppressor pathway that is commonly mutated in renal cell carcinoma. These mechanisms are consistent with the epidemiological evidence and provide a biologically plausible explanation for the observed association.
Kidney Cancer Claims in the AFFF Litigation
Kidney cancer claims represent some of the highest-valued cases in MDL 2873 due to the strength of the causation science. Plaintiffs with kidney cancer who can document PFAS exposure — through firefighting employment records, military service records at contaminated bases, or residential history in contaminated communities — have a clear scientific basis for their claims supported by IARC Group 1 classification and C8 Science Panel "probable link" determination.
The C8 bellwether trials established the viability of kidney cancer claims against PFAS manufacturers. Carla Bartlett received a $1.6 million jury verdict in 2015 for kidney cancer caused by PFOA exposure from DuPont's Washington Works facility. This verdict — and the subsequent global settlement of approximately 3,550 C8 claims for $670.7 million — demonstrated that juries will hold manufacturers accountable for PFAS-linked kidney cancer.
Kidney cancer is often diagnosed at advanced stages because early-stage disease is frequently asymptomatic. For AFFF-exposed individuals, awareness of the PFAS-kidney cancer link is critical for early detection. Anyone with significant AFFF exposure should discuss enhanced kidney screening (including periodic CT scans or ultrasounds) with their healthcare provider, even in the absence of symptoms.
Scientific Evidence
Meta-Analysis of PFAS Exposure and Cancer Risk: Kidney and Testicular Cancer
Mastrantonio M, Bai E, Uccelli R, Cordiano V, Screpanti A, Corigliano P. (2023). La Medicina del Lavoro
Key Findings
- Relative risk of 1.74 for kidney cancer among individuals with high PFAS exposure compared to low-exposure controls
- Relative risk of 2.22 for testicular cancer among individuals with high PFAS exposure — the strongest relative risk of any PFAS-cancer association
- Dose-response relationship demonstrated: higher PFAS blood levels correlated with progressively higher cancer risk
- Results consistent across multiple study designs and populations, strengthening the causal inference
"The Devil They Knew": Industry Knowledge of PFAS Dangers Since 1970
Brennan NM, Evans AT, Fritz MK, Peak SA, von Holst HE. (2023). Annals of Global Health
Key Findings
- PFAS manufacturers knew about the persistence and toxicity of their products as early as 1970 — more than 50 years before widespread public awareness
- 3M conducted internal studies showing PFAS bioaccumulation in worker blood at 1,000 times normal levels and animal studies showing tumor formation, then classified results as confidential
- Manufacturers used trade secret protections and proprietary research agreements to prevent damaging findings from reaching regulators or the public
- The pattern of corporate concealment parallels the tobacco and asbestos industries and supports punitive damages claims based on willful and malicious conduct
C8 Science Panel: Probable Link Evaluations for PFOA-Associated Diseases
Fletcher T, Savitz D, Steenland K. (2012). Environmental Health Perspectives
Key Findings
- Determined "probable link" between PFOA exposure and six diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension
- Study population of 69,000 residents made it one of the largest PFAS health studies ever conducted, providing exceptional statistical power
- Findings have been cited in virtually every subsequent PFAS lawsuit and regulatory action worldwide
- The "probable link" standard — requiring more than just association but less than definitive proof — was a negotiated scientific threshold that has become the benchmark for PFAS causation evidence
Frequently Asked Questions
Related Pages
3M & DuPont PFAS Lawsuit
3M and DuPont are the two primary defendants in the AFFF/PFAS litigation. 3M manufactured PFOS-based AFFF from the 1960s and has already paid $10.3 billion in water utility settlements and $850 million to Minnesota. DuPont manufactured PFOA and was the target of the landmark Bilott litigation that created the C8 Science Panel. Internal documents from both companies show they knew about PFAS toxicity for decades and concealed it. Their corporate successors — Chemours, Corteva, and others — share in the liability.
AFFF Firefighter Cancer Claims
Firefighters have the highest documented PFAS blood levels of any occupational group and form the core of the AFFF personal injury litigation. Municipal, airport, and military firefighters who trained with AFFF absorbed PFAS through skin contact and inhalation of foam mist, often for years or decades without protective equipment. NIOSH studies show elevated cancer rates among firefighters, and many states have enacted presumptive cancer laws that create favorable conditions for firefighter AFFF claims.
AFFF Military Base Contamination
The Department of Defense has identified PFAS contamination at more than 455 military installations where AFFF was used for fire training and emergency response. Air Force bases, Naval air stations, and Marine Corps installations are the most heavily affected. Service members, their families, and surrounding communities were exposed for decades through contaminated drinking water. Military personnel can file AFFF lawsuits against the foam manufacturers while also receiving VA benefits.
AFFF Settlement Amounts
AFFF/PFAS litigation has produced over $12.5 billion in water utility settlements and $670.7 million in C8 personal injury settlements. The personal injury track in MDL 2873 — with 15,216+ claims — is advancing toward bellwether trials that will establish settlement benchmarks. Based on the C8 precedent (averaging ~$189,000 per claim) and the severity of PFAS-linked conditions, projected personal injury settlements range from $25,000 for moderate cases to $2 million or more for severe cases.
AFFF Testicular Cancer Lawsuit
Testicular cancer has the highest relative risk of any PFAS-linked cancer, with meta-analyses showing RR=2.22 for high PFAS exposure — meaning more than double the cancer risk. The C8 Science Panel determined a "probable link" between PFOA and testicular cancer. Testicular cancer is most common in younger men (ages 15-35), making it particularly relevant for military personnel and younger firefighters exposed to AFFF early in their careers.
AFFF Thyroid Disease Lawsuit
Thyroid disease is one of six conditions with a C8 Science Panel "probable link" to PFOA exposure. PFAS are potent endocrine disruptors that interfere with thyroid hormone synthesis and metabolism, causing hypothyroidism, hyperthyroidism, and thyroid cancer. Thyroid disease is often the earliest clinical manifestation of PFAS exposure and may affect a broader population than PFAS-linked cancers, making it significant for the AFFF litigation.
AFFF Water Contamination Lawsuit
PFAS from AFFF have contaminated the drinking water of an estimated 100 million Americans. Water utility settlements exceeding $12.5 billion have been approved in MDL 2873, but personal injury claims from individuals who drank contaminated water remain active. The EPA's 2024 drinking water standard of 4 ppt for PFOA/PFOS confirmed that previously "safe" levels were actually harmful. Community residents who developed PFAS-linked diseases from contaminated water have viable personal injury claims.
AFFF Firefighting Foam Lawsuit
AFFF firefighting foam containing per- and polyfluoroalkyl substances (PFAS) has been used since the 1960s at military bases, airports, and fire training facilities across the United States. These "forever chemicals" do not break down in the environment and have contaminated groundwater, soil, and drinking water supplies serving millions of Americans. The C8 Science Panel established "probable links" between PFAS exposure and six diseases including kidney cancer, testicular cancer, and thyroid disease. MDL 2873, consolidated before Judge Richard Gergel in the District of South Carolina, encompasses over 15,216 personal injury claims against manufacturers including 3M, DuPont, Chemours, Tyco Fire Products, and BASF. Water utility settlements exceeding $12.5 billion have been approved, and the personal injury track is advancing toward bellwether trials with Daubert motions and expert depositions underway.
View full case overview